Viral proteases as therapeutic targets

被引:25
作者
Majerova, Tatana [1 ]
Konvalinka, Jan [1 ,2 ]
机构
[1] Czech Acad Sci, Inst Organ Chem & Biochem, Flemingovo Nam 2, Prague 16610 6, Czech Republic
[2] Charles Univ Prague, Fac Sci, Dept Biochem, Prague 12843, Czech Republic
关键词
HEPATITIS-C-VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; ORALLY BIOAVAILABLE INHIBITOR; STRUCTURE-BASED OPTIMIZATION; TYPE-1 GAGPOL PRECURSOR; STRUCTURE-BASED DESIGN; HIV-1; PROTEASE; GENOTYPE; NS3/4A PROTEASE; DRUG-RESISTANCE;
D O I
10.1016/j.mam.2022.101159
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Some medically important viruses-including retroviruses, flaviviruses, coronaviruses, and herpesviruses-code for a protease, which is indispensable for viral maturation and pathogenesis. Viral protease inhibitors have become an important class of antiviral drugs. Development of the first-in-class viral protease inhibitor saquinavir, which targets HIV protease, started a new era in the treatment of chronic viral diseases. Combining several drugs that target different steps of the viral life cycle enables use of lower doses of individual drugs (and thereby reduction of potential side effects, which frequently occur during long term therapy) and reduces drug-resistance development. Currently, several HIV and HCV protease inhibitors are routinely used in clinical practice. In addition, a drug including an inhibitor of SARS-CoV-2 main protease, nirmatrelvir (co-administered with a pharmacokinetic booster ritonavir as Paxlovid (R)), was recently authorized for emergency use. This review summarizes the basic features of the proteases of human immunodeficiency virus (HIV), hepatitis C virus (HCV), and SARS-CoV-2 and discusses the properties of their inhibitors in clinical use, as well as development of compounds in the pipeline.
引用
收藏
页数:24
相关论文
共 394 条
[71]   Temporal Response of the Human Virome to Immunosuppression and Antiviral Therapy [J].
De Vlaminck, Iwijn ;
Khush, Kiran K. ;
Strehl, Calvin ;
Kohli, Bitika ;
Luikart, Helen ;
Neff, Norma F. ;
Okamoto, Jennifer ;
Snyder, Thomas M. ;
Cornfield, David N. ;
Nicolls, Mark R. ;
Weill, David ;
Bernstein, Daniel ;
Valantine, Hannah A. ;
Quake, Stephen R. .
CELL, 2013, 155 (05) :1178-1187
[72]   Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection [J].
de Wit, Emmie ;
Feldmann, Friederike ;
Cronin, Jacqueline ;
Jordan, Robert ;
Okumura, Atsushi ;
Thomas, Tina ;
Scott, Dana ;
Cihlar, Tomas ;
Feldmann, Heinz .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2020, 117 (12) :6771-6776
[73]  
DECLERCQ E, 1987, ANTICANCER RES, V7, P1023
[74]   HIV protease inhibitors elicit volume-sensitive Cl- current in cardiac myocytes via mitochondrial ROS [J].
Deng, Wu ;
Baki, Lia ;
Yin, Jun ;
Zhou, Huiping ;
Baumgarten, Clive M. .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2010, 49 (05) :746-752
[75]   Coronaviruses An RNA proofreading machine regulates replication fidelity and diversity [J].
Denison, Mark R. ;
Graham, Rachel L. ;
Donaldson, Eric F. ;
Eckerle, Lance D. ;
Baric, Ralph S. .
RNA BIOLOGY, 2011, 8 (02) :270-279
[76]  
Dienstag J.L., 2015, MANDELL DOUGLAS BENN, Veighth
[77]   Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir [J].
Doyon, L ;
Tremblay, S ;
Bourgon, L ;
Wardrop, E ;
Cordingley, MG .
ANTIVIRAL RESEARCH, 2005, 68 (01) :27-35
[78]   Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors.: 4.: Incorporation of P1 lactam moieties as L-glutamine replacements [J].
Dragovich, PS ;
Prins, TJ ;
Zhou, R ;
Webber, SE ;
Marakovits, JT ;
Fuhrman, SA ;
Patick, AK ;
Matthews, DA ;
Lee, CA ;
Ford, CE ;
Burke, BJ ;
Rejto, PA ;
Hendrickson, TF ;
Tuntland, T ;
Brown, EL ;
Meador, JW ;
Ferre, RA ;
Harr, JEV ;
Kosa, MB ;
Worland, ST .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (07) :1213-1224
[79]   Seasonal and pandemic influenza: 100 years of progress, still much to learn [J].
Dunning, Jake ;
Thwaites, Ryan S. ;
Openshaw, Peter J. M. .
MUCOSAL IMMUNOLOGY, 2020, 13 (04) :566-573
[80]   Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy [J].
Dustin, L. B. ;
Bartolini, B. ;
Capobianchi, M. R. ;
Pistello, M. .
CLINICAL MICROBIOLOGY AND INFECTION, 2016, 22 (10) :826-832